NCT Number: NCT02455505
Identifying Family Members in Need of Support While Caregiving and After Loss
This screening tool will be used to identify significant relations of patients with advanced medical illness or serious hospitalization and family individuals who lost their loved one and who could use professional support in the future. We are interested in enrolling family members or close friends of patients with advanced medical illness as well as family members or close friends who have lost a loved one. Some screening tools to identify family members who might need support do exist, but the investigators are hoping to develop one that is brief and easier for healthcare providers to use. The information learned in this study will help us refine the screening tool. Family member input will be essential in the development of this screening tool.
This study is active but is not currently recruiting participants.
Notify MeKey information
Conditions
Age range
21 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Memorial Sloan Kettering Cancer Center, New York, United States
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- As per self-report, 21 years or older
- As per self-report, has a domestic partner or spouse, child (minor or adult), sibling (sister or brother), parent or close friend diagnosed with any advanced medical illness or who was recently (2 months) or is currently hospitalized for life-threatening injuries or conditions related to a traumatic incident (e.g., car accident, overdose, assault) OR
- As per self-report, experienced the recent (within 2 months to 3 years) death of a domestic partner or spouse, child (minor or adult), sibling, parent or close friend.
- Responds "yes" to the question "Can you understand spoken and written English?
- Agrees to be audio-taped during the cognitive interview [Waves 1 and 2 only] * For Part 2 only: In the event that the patient dies prior to a consenting pre-loss family member completing the study questionnaires, the family member will be eligible for participation in the post-loss group after at least 2 months have passed after the loss
Exclusion criteria
- Significant psychiatric or cognitive disturbance sufficient, in the investigators' judgment, to preclude the completion of the assessment measures or informed consent (i.e., acute psychiatric or neurological symptoms which require individual treatment)
- Another family member (parent, domestic partner or spouse, sibling, or adult child) has been enrolled in the study
Treatment and study plan
bereavement risk screening tool
BehavioralPrimary outcomes
-
to refine the bereavement risk screening tool and its items based on respondent feedback.
Time frame: 1 year
we will obtain family member input on the pre- and post-loss versions of the screening tool; we will obtain input from a separate sample of family members on a revised version of the screening tool that incorporates feedback
Sponsors and collaborators
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Collaborators
- Calvary Hospital, Bronx, NY
- The New School for Social Research
- Weill Medical College of Cornell University
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- May 28, 2015
- Registry last updated
- Jun 2, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Adenocarcinoma, Adnexal Diseases
Phoenix, Arizona, United States
View Trial DetailsA Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553
Advanced Cancer, Biliary Tract Cancer
Tucson, Arizona, United States
View Trial DetailsSirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
NCT01087554
Advanced Cancer
Houston, Texas, United States
View Trial DetailsMeaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer
NCT04435444
Advanced Cancer
New York, United States
View Trial Details